Stoke Therapeutics
Cash Flow
Last updated:
Cash flow statement presents a set of outflows and inflows of cash within a company through operating, investing and financing activities. Over the last year, operating activities of Stoke Therapeutics generated cash of -$81,067,000, which is less than the previous year. Cash used in financing activities reached the amount of $53,007,000 last year. Net change in cash is therefore $77,886,000.
Cash Flow
| 2017 | -5.38M | -113K | 5.97M |
|---|---|---|---|
| 2018 | -10.96M | -925K | 115.63M |
| 2019 | -31.05M | -1.63M | 149.76M |
| 2020 | -42.22M | -1.05M | 108.10M |
| 2021 | -66.90M | -76.42M | 1.28M |
| 2022 | -31.86M | -45.88M | 46.40M |
| 2023 | -81.06M | 105.94M | 53.00M |
STOK Cash Flow Statement (2017 – 2023)
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | |
|---|---|---|---|---|---|---|---|
Cash at beginning of period | 114.12M | 145.46M | 287.51M | 222.67M | 105.60M | 1.85M | 1.37M |
Operating activities | |||||||
Net income | -104.69M | -101.06M | -85.80M | -52.24M | -32.32M | -12.52M | -5.55M |
| Adjustments to reconcile net income to cash generated by operating activities: | |||||||
Depreciation and amortization | 2.46M | 1.54M | 974K | 888K | 450K | 214K | 113K |
Stock-based compensation expense | 25.25M | 22.85M | 16.45M | 5.76M | 1.92M | 0 | 26K |
| Deferred income tax benefit | 25.25M | 22.85M | 16.45M | 5.76M | 1.92M | 0 | 26K |
| Changes in operating assets and liabilities: | |||||||
Accounts receivable, net | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Inventories | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Accounts payable | -3.20M | 121K | 2.89M | 5.20M | 891K | 0 | 100K |
Cash generated by operating activities | -81.06M | -31.86M | -66.90M | -42.22M | -31.05M | -10.96M | -5.38M |
Investing activities | |||||||
Purchases Of Investments | 0 | -201.32M | -87.22M | 0 | 0 | 0 | 0 |
Investments In Property Plant And Equipment | -1.61M | -3.96M | -1.2M | -1.05M | -1.63M | -935K | -113K |
Acquisitions Net | 0 | 45.34M | 75.22M | 0 | 1K | 0 | 0 |
Cash generated by investing activities | 105.94M | -45.88M | -76.42M | -1.05M | -1.63M | -925K | -113K |
Financing activities | |||||||
Common Stock Issued | 52.08M | 45.34M | 1.28M | 105.39M | 151.91M | 0 | 2.97M |
Payments for dividends | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Repurchases of common stock | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Repayments of term debt | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Cash used in financing activities | 53.00M | 46.40M | 1.28M | 108.10M | 149.76M | 115.63M | 5.97M |
Net Change In Cash | 77.88M | -31.33M | -142.04M | 64.83M | 117.07M | 103.75M | 477K |
Cash at end of period | 192.01M | 114.12M | 145.46M | 287.51M | 222.67M | 105.60M | 1.85M |
| Data source | Data source | Data source | Data source | Data source |